Innovative Bispecific Nanobody Targeting FCGR3A and MUC1 for Next-Generation Cancer Therapy

VHH-P744 is a fully humanized nanobody-based bispecific T-cell engager developed to target both Fc gamma receptor IIIa (FCGR3A) and mucin 1, cell surface associated (MUC1). Currently in the Biological Testing stage, VHH-P744 holds promise for the treatment of cancer by recruiting and activating immune cells directly at the tumor site. With its unique dual-target design, VHH-P744 offers a pioneering approach for addressing the complex tumor microenvironment, aiming to enhance therapeutic efficacy through precise tumor recognition and immune cell engagement. Its innovative mechanism leverages the latest advances in immuno-oncology to potentially overcome current limitations in cancer therapies.

Licensing Opportunity

VHH-P744 is currently available for licensing and collaboration opportunities. Partners interested in advancing innovative cancer immunotherapy solutions are welcome to discuss co-development, out-licensing, or strategic partnership arrangements.

Development Phase

Modality

VHH-P744 utilizes a bispecific nanobody structure, consisting of two heavy chain variable domains (VHHs) specific for MUC1 and FCGR3A (CD16), connected via a flexible GS linker. Expressed in E. coli BL21 (DE3) and formulated with PLGA nanoparticles, this modality offers significant advantages, including small molecular size for superior tumor tissue penetration and robust stability under physiological conditions. Nanobodies are highly resistant to aggregation and can be produced efficiently in microbial systems, enabling scalable production. The bispecific design enhances the targeted recruitment and activation of immune cells within tumors, making VHH-P744 particularly advantageous for cancer treatment where deep tumor infiltration and strong immune activation are critical.

Target

FCGR3A is a receptor expressed primarily on natural killer (NK) cells and some populations of macrophages and granulocytes, facilitating antibody-dependent cellular cytotoxicity (ADCC). MUC1 is a highly glycosylated transmembrane protein overexpressed and aberrantly glycosylated in many epithelial cancers, contributing to tumor growth, metastasis, and immune evasion. Both FCGR3A and MUC1 are well-validated targets in cancer immunotherapy; FCGR3A enables direct engagement of innate immune defenses, while MUC1 provides tumor specificity. VHH-P744 strategically targets both FCGR3A and MUC1, thereby facilitating efficient immune cell-mediated tumor cell killing. This dual targeting offers substantial value by maximizing anti-tumor effects and addressing tumor immune escape mechanisms, positioning VHH-P744 as a competitive asset in the oncology field.

Mechanism of Action

VHH-P744 operates as a bispecific nanobody that simultaneously binds MUC1 on tumor cells and FCGR3A on NK cells. By bridging these two cell types, VHH-P744 acts as an NK-cell engager, promoting targeted immune synapse formation and subsequent tumor cell lysis. The design enables selective recruitment and activation of NK cells at the tumor site, leveraging antibody-dependent cellular cytotoxicity to eliminate malignant cells expressing MUC1. The use of single-domain VHHs confers high stability and versatility, providing a robust platform for further development into antibody-drug conjugates or multispecific formats to address various cancer types and resistance mechanisms. This mechanism may lead to more durable and potent anti-tumor responses while minimizing off-target effects.

Cancer

Cancer remains one of the leading causes of death worldwide, encompassing a diverse group of diseases characterized by uncontrolled cell proliferation and potential to metastasize to other body parts. Risk factors include genetic predispositions, environmental exposures, and lifestyle behaviors. The epidemiology of cancer reveals a rising global incidence, especially in aging populations. Current standard therapies include surgery, radiation, chemotherapy, immunotherapy, and targeted therapies, each with distinct advantages and limitations. Despite recent advances, challenges such as tumor heterogeneity, immune evasion, toxicity from nonspecific treatments, and drug resistance persist, leading to unmet medical needs. The introduction of novel immunotherapeutic approaches, such as VHH-P744, has the potential to address these gaps by offering precise, potent, and tumor-selective immune activation. VHH-P744’s dual-targeting nanobody approach may improve clinical outcomes for cancer patients who have limited options with existing treatments.